Fig. 3: Comparison of estimated Pfizer vaccine-associated myocarditis cases to symptomatic COVID-19 cases and deaths prevented. | npj Vaccines

Fig. 3: Comparison of estimated Pfizer vaccine-associated myocarditis cases to symptomatic COVID-19 cases and deaths prevented.

From: A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia

Fig. 3

Estimated COVID-19 cases (a) and deaths (b) (in log scale) prevented by age group over 2 months per million population if 5% of population of ages ≥12 years had no doses, 5% had first dose, 60% had two doses (evenly distributed over 0 to < 2, 2 to < 4 and 4 to < 6 months since second dose) and 30% had three doses of Pfizer COVID-19 vaccine if community transmission equivalent to 1% (green), 5% (yellow) and 10% (orange) chance of infection over 2 months. c Estimated cases of Pfizer COVID-19 vaccine-associated myocarditis over 2 months under the same vaccine coverage.

Back to article page